β-受体阻滞剂在充血性心力衰竭治疗中的作用

The role ofβ-blockers in the treatment of congestive heart failure

目的探究β-受体阻滞剂在充血性心力衰竭(CHF)治疗中的效果。方法94例CHF患者,按随机数字表法分为对照组及观察组,每组47例。对照组使用常规治疗,观察组在对照组基础上加用美托洛尔治疗。对比两组临床疗效、心功能及不良反应发生情况。结果观察组治疗总有效率95.74%高于对照组的82.98%,差异有统计学意义(P<0.05)。治疗前,两组左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)对比,差异无统计学意义(P>0.05);治疗30 d后,两组LVEF高于本组治疗前,LVESD、LVEDD小于本组治疗前,且观察组LVEF(47.36±4.51)%高于对照组的(42.65±3.28)%,LVESD(42.38±3.85)mm、LVEDD(48.67±3.95)mm小于对照组的(46.56±4.63)、(53.58±4.36)mm,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论美托洛尔能够有效改善CHF患者心功能,加快病情恢复,且无严重不良反应,安全可行。

Objective To investigate the effect ofβ-blockers in the treatment of congestive heart failure(CHF).Methods A total of 94 patients with CHF were randomly divided into control group and observation group,with 47 patients in each group.The control group was treated with conventional therapy,while the observation group was treated with metoprolol on the basis of the control group.The clinical efficacy,cardiac function and occurrence of adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 95.74%,which was higher than 82.98%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),and left ventricular end diastolic diameter(LVEDD)between the two groups(P>0.05).After 30 d of treatment,the LVEF in the two groups was higher than that before treatment in this group,and the LVESD and LVEDD were lower than those before treatment in this group;the LVEF(47.36±4.51)%in the observation group was higher than(42.65±3.28)%in the control group;the LVESD(42.38±3.85)mm and LVEDD(48.67±3.95)mm in the observation group were lower than(46.56±4.63)and(53.58±4.36)mm in the control group;the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Metoprolol can effectively improve the cardiac function of CHF patients,accelerate the recovery of the disease,and it is safe and feasible without serious adverse reactions.